Sun Pharma FY24 Sept qtr net profit grows 5% to Rs 2,376 cr
Mumbai: Leading pharma company Sun Pharmaceutical Industries Ltd Wednesday reported a 5% increase in its net profit for the July-September quarter, reaching Rs 2,375.5 crore compared to Rs 2,262.2 crore in the corresponding period last year.

This marks a 17.4% rise from the previous quarter's net profit of Rs 2,022.5 crore.
The company's revenue from operations saw an 11.3% uptick, amounting to Rs 12,192.4 crore in the quarter, up from Rs 10,952.2 crore in the same period last year.
Sun Pharma's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) stood at Rs 3,179 crore, with a margin of 26.1%.
In a recent development, the company revealed that the United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for deucruxitinib, an oral selective inhibitor targeting Janus kinases JAK1 and JAK2. This application seeks approval for the treatment of adults with moderate to severe alopecia areata, an autoimmune condition causing partial or complete hair loss on the scalp and body.
Furthermore, Zydus Lifesciences announced a partnership with Sun Pharma to distribute an oral treatment for anaemia associated with chronic kidney disease (CKD) in the country.
"The companies have entered into a licensing agreement to co-market the innovative drug, Desidustat, in India," Zydus said in a regulatory filing.
As per the terms outlined in the agreement, Zydus has provided Sun Pharma with semi-exclusive rights to collaborate in marketing the product in India. Under this collaboration, Sun Pharma market the drug under the brand name "Rytstat."
IBNS
Senior Staff Reporter at Northeast Herald, covering news from Tripura and Northeast India.
Related Articles

CRR cut, AI ethics push, and SORR benchmark: Experts hail RBI’s pragmatic policy moves
Mumbai: The Reserve Bank of India (RBI) has kept the repo rate unchanged at 6.5% while the cash reserve ratio (CRR) has been slashed by 50 basis points to 4 percent, media reports said.

JP Morgan gives 'overweight' rating to Adani Group bonds
Mumbai: US investment bank JP Morgan has assigned an 'overweight' rating to four bonds issued by the Adani Group, citing the group's capacity to scale and grow through internal cash flows, which reduces the likelihood of credit stress.

LG Electronics files DRPH with SEBI; IPO size expected to be over RS 15,000 cr
Mumbai: South Korean electronics giant LG Electronics has filed a draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) on Friday for the proposed public listing of its Indian business, according to a notification on the Bombay Stock Exchange (BSE).

De-dollarisation not on India's agenda; derisking domestic trade is: RBI Governor Shaktikanta Das
Mumbai: India has not initiated any steps towards de-dollarisation and is solely focused on mitigating risks to domestic trade from geopolitical uncertainties, Reserve Bank of India (RBI) Governor Shaktikanta Das clarified on Friday, media reports said.
Latest News

Two children die, several get ill after consuming cough syrup in Rajasthan

J&K: Mehbooba Mufti accuses BJP of forcing people to stand for national anthem at ‘gunpoint’

Shoaib Akhtar slams PCB after Asia Cup 2025 final loss, calls it ‘senseless and headless chicken’

PM Modi releases ₹100 coin, says first-ever Bharat Mata image carved on currency
